ImmuPharma plc (LON:IMM – Get Free Report)’s stock price was up 13.4% during mid-day trading on Wednesday . The company traded as high as GBX 10.80 and last traded at GBX 10.50. Approximately 7,242,426 shares were traded during trading, a decline of 10% from the average daily volume of 8,073,004 shares. The stock had previously closed at GBX 9.26.
ImmuPharma Price Performance
The firm has a 50-day moving average of GBX 10.98 and a 200 day moving average of GBX 5.43. The company has a market capitalization of £52.79 million, a PE ratio of -11.80 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- Should You Invest in Penny Stocks?
- Rare Earth Stocks: The Truce That Isn’t a Truce
- What Is WallStreetBets and What Stocks Are They Targeting?
- Carving Up Profits: 3 Food Stocks on the Thanksgiving Table
- Pros And Cons Of Monthly Dividend Stocks
- C3.ai’s Reset: Why New Leadership Could Spark a Turnaround
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
